HUTCHMED (NASDAQ:HCM) Sets New 1-Year Low – Here’s Why

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) reached a new 52-week low on Wednesday . The company traded as low as $12.53 and last traded at $12.67, with a volume of 28148 shares. The stock had previously closed at $12.87.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HCM. Wall Street Zen downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings downgraded HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 1st. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Bank of America dropped their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, HUTCHMED has a consensus rating of “Hold” and an average target price of $16.88.

HUTCHMED Stock Down 1.6%

The business has a fifty day moving average of $14.27 and a 200 day moving average of $14.46. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings data on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. On average, equities research analysts predict that HUTCHMED will post 0.41 EPS for the current year.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HCM. XY Capital Ltd grew its stake in HUTCHMED by 291.1% in the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock valued at $831,000 after acquiring an additional 39,266 shares during the period. Vanguard Personalized Indexing Management LLC grew its stake in HUTCHMED by 12.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after acquiring an additional 1,873 shares during the period. Goldman Sachs Group Inc. grew its stake in HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after acquiring an additional 7,342 shares during the period. Dimensional Fund Advisors LP grew its stake in HUTCHMED by 157.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after acquiring an additional 34,248 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after acquiring an additional 4,116 shares during the period. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.